PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

Bibliographic Details
Main Authors:	C. Cerchione, G. Musuraca, B. Giannini, D. Nappi, F. Alfinito, G. Martinelli
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000851880.74291.06

Similar Items

2263
by: Corbin Daniel Ester, et al.
Published: (2017-09-01)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
by: S. Mukherjee, et al.
Published: (2022-06-01)

Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
by: Tilman B. Drüeke
Published: (2018-11-01)

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
by: Sheila Weiss Smith, et al.
Published: (2012-01-01)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
by: Horváth-Puhó E, et al.
Published: (2018-09-01)

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
by: Olivier Kosmider, et al.
Published: (2016-07-01)

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes
by: Amy J. Davidoff, et al.
Published: (2012-01-01)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
by: Ana Cristina Gonçalves, et al.
Published: (2021-06-01)

ErythropoieSIS stimulating agent (ESA) use is increased following missed dialysis sessions
by: T. Christopher Bond, et al.
Published: (2012-06-01)

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes
by: Juan Carlos Caballero, et al.
Published: (2024-01-01)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
by: Ylenia Ingrasciotta, et al.
Published: (2019-09-01)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
by: C. Cerchione, et al.
Published: (2022-06-01)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
by: Kmira Zahra, et al.
Published: (2023-08-01)

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
by: C. Cerchione, et al.
Published: (2022-06-01)

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
by: Ylenia Ingrasciotta, et al.
Published: (2020-07-01)

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
by: C. Cerchione, et al.
Published: (2022-06-01)

Increases In Erythropoiesis Stimulating Agent (Esa) Use After Hospitalization Of End Stage Renal Disease (Esrd) Patients
by: T. Christopher Bond, et al.
Published: (2012-06-01)

p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes
by: Emilie Frisan, et al.
Published: (2010-11-01)

Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor
by: Kirtan Nautiyal, et al.
Published: (2015-01-01)

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
by: Müzeyyen Aslaner Ak, et al.
Published: (2023-06-01)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
by: C. Cerchione, et al.
Published: (2022-06-01)

Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice
by: Wenbin An, et al.
Published: (2023-12-01)

Appropriate Use of Inpatient Erythropoiesis Stimulating Agents
by: Chenghao Cui, et al.
Published: (2024-11-01)

Erythropoiesis stimulating agents approaches to modulate activity
by: Sinclair AM
Published: (2013-07-01)

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
by: George Pavlidis, et al.
Published: (2021-01-01)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
by: Patrick Biggar, et al.
Published: (2017-09-01)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
by: Sun-Hee Park
Published: (2018-09-01)

PB1918: MOLECULAR CHARACTERIZATION AND CLINICAL RELEVANCE OF ERYTHROPOIESIS IN MIELODYSPLASTIC SYNDROMES.
by: A. Villalba, et al.
Published: (2022-06-01)

Timing-adjusted iron dosing enhances erythropoiesis-stimulating agent-induced erythropoiesis response and iron utilization
by: Tomoyuki Kawano, et al.
Published: (2017-05-01)

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study
by: Emanuela Messa, et al.
Published: (2019-01-01)

Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents
by: N. A. Romanenko, et al.
Published: (2014-07-01)

Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents
by: N. A. Romanenko, et al.
Published: (2014-07-01)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
by: Jay B. Wish
Published: (2020-09-01)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
by: Uwe Platzbecker, et al.
Published: (2023-08-01)

The effects of chronic glucorticoid stimulation on erythropoiesis in Cushing syndrome
by: John Strouboulis, et al.
Published: (2022-07-01)

2263 Creating a reference analytics morphomics population from surgical patient cross-sectional imaging
by: Katherine He, et al.
Published: (2018-06-01)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
by: Nouha Bouayed Abdelmoula, et al.
Published: (2023-08-01)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
by: Hirokazu Honda, et al.
Published: (2016-01-01)